Sung S J, Silverstein S C
J Biol Chem. 1985 Jan 10;260(1):546-54.
Adenosine (Ado), deoxyadenosine (dAdo), and adenine arabinoside (AraA) inhibit the phagocytosis of IgG-coated erythrocytes and zymosan by resident and thioglycollate-elicited macrophages (thio-macrophages) in a dose-dependent and reversible manner. 3-Deazaadenosine (3cAdo) and adenine (Ade) also inhibit the phagocytosis by resident macrophages. Homocysteine thiolactonate (Hcy) potentiates the inhibition by Ado and 3cAdo while erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) potentiates the inhibition by Ado, dAdo and AraA. This inhibition has a very rapid onset and the drugs do not interfere with the binding of IgG-coated erythrocytes to macrophages. The combination of Ado, Hcy and EHNA does not appreciably affect the intracellular level of ATP and S-adenosyl-L-methionine (AdoMet) in thio-macrophages but causes accumulations of Ado and S-adenosyl-L-homocysteine (AdoHcy) up to 135 and 145 nmol/mg of protein, respectively. During phagocytosis reversal, Ado is metabolized within 15 min while AdoHcy decreases log-arithmically with a half-life of 50 min. Carboxymethylation and phospholipid methylation, however, resume about 60-90 min after phagocytosis has recovered, and thus cannot function as transmembrane signals for phagocytosis. Other evidence showing the lack of correlation between phagocytosis and carboxymethylation inhibition include 1) Ado + Hcy inhibit carboxymethylation much better than Ado + EHNA (91 versus 75%) in thio-macrophage, but the two combinations show comparable phagocytosis inhibition potency; 2) Ado + Hcy inhibit carboxymethylation almost as well as Ado + Hcy + EHNA, but the latter is a much more effective drug combination for phagocytosis inhibition; 3) Ade and 3cAdo, although inhibiting resident macrophage phagocytosis as well as Ado + EHNA + Hcy, are much weaker carboxymethylation inhibitors; 4) dAdo and AraA potently inhibit phagocytosis but not carboxymethylation. The difference in the apparent methylation levels is not due to changes in the specific activities of AdoMet, which decrease with a half-life of 88 min. Interestingly, after the initial lag phase of about 90 min after the initiation of inhibition reversal, carboxymethylation and phagocytosis increase in parallel. In a log-log plot of carboxymethylation, phospholipid methylation, or phagocytosis versus the intracellular AdoHcy accumulation, a linear relationship is obtained. It is possible that AdoHcy accumulation is responsible for phagocytosis inhibition but inhibits by a mechanism other than interfering with protein and lipid methylations.
腺苷(Ado)、脱氧腺苷(dAdo)和阿糖腺苷(AraA)以剂量依赖且可逆的方式抑制驻留型和巯基乙酸盐诱导的巨噬细胞(硫代巨噬细胞)对IgG包被红细胞和酵母聚糖的吞噬作用。3 - 去氮腺苷(3cAdo)和腺嘌呤(Ade)也抑制驻留型巨噬细胞的吞噬作用。同型半胱氨酸硫内酯(Hcy)增强Ado和3cAdo的抑制作用,而赤藓红 - 9 -(2 - 羟基 - 3 - 壬基)腺嘌呤(EHNA)增强Ado、dAdo和AraA的抑制作用。这种抑制作用起效非常迅速,且这些药物不干扰IgG包被红细胞与巨噬细胞的结合。Ado、Hcy和EHNA的组合对硫代巨噬细胞内ATP和S - 腺苷 - L - 甲硫氨酸(AdoMet)的细胞内水平没有明显影响,但会分别导致Ado和S - 腺苷 - L - 同型半胱氨酸(AdoHcy)积累至135和145 nmol/mg蛋白质。在吞噬作用逆转过程中,Ado在15分钟内被代谢,而AdoHcy以对数形式下降,半衰期为50分钟。然而,羧甲基化和磷脂甲基化在吞噬作用恢复后约60 - 90分钟才恢复,因此不能作为吞噬作用的跨膜信号。其他表明吞噬作用与羧甲基化抑制之间缺乏相关性的证据包括:1)在硫代巨噬细胞中,Ado + Hcy比Ado + EHNA能更好地抑制羧甲基化(91%对75%),但这两种组合显示出相当的吞噬作用抑制效力;2)Ado + Hcy几乎与Ado + Hcy + EHNA一样能抑制羧甲基化,但后者是一种对吞噬作用抑制更有效的药物组合;3)Ade和3cAdo虽然与Ado + EHNA + Hcy一样能抑制驻留型巨噬细胞的吞噬作用,但它们是较弱的羧甲基化抑制剂;4)dAdo和AraA能有效抑制吞噬作用但不抑制羧甲基化。表观甲基化水平的差异并非由于AdoMet比活性的变化,AdoMet比活性以88分钟的半衰期下降。有趣的是,在抑制作用逆转开始约90分钟的初始延迟期后,羧甲基化和吞噬作用平行增加。在羧甲基化、磷脂甲基化或吞噬作用与细胞内AdoHcy积累的双对数图中,得到线性关系。有可能AdoHcy积累是吞噬作用抑制的原因,但通过不同于干扰蛋白质和脂质甲基化的机制起作用。